Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Even the government has plumbing problems

Executive Summary

"As soon as they put it in front of me to sign," Office of New Drugs Director John Jenkins says, he will sign a memorandum of agreement setting out the duties of OND and Office of Safety and Epidemiology staff in reviewing safety issues for new drugs. A scheduled June 16 signing of the memo by Jenkins and OSE Director Gerald Dal Pan was delayed when a broken water main closed some FDA offices. Personnel in the two offices already are operating under the new procedures, the two assured those attending a June 26 town hall meeting during the Drug Information Association meeting in Boston. If staff cannot resolve their differences, the agreement calls for passing decisions up to the two office directors and then to CDER Director Janet Woodcock, if necessary. The latter will be a "rare occurrence," Jenkins and Dal Pan insist

You may also be interested in...

FDA Drug Review, Surveillance Offices Agree To Share Safety Authority

FDA's drug review and drug safety offices have set aside their differences and laid out an agreement that more equally divides regulatory authority on issues related to drug safety

Humira LOE Is ‘Uncharted Territory’ As Fierce Competition Expected

Discussing the latest developments in the US biosimilars market, AmerisourceBergen’s senior director of biosimilar commercialization, Brian Biehn, talks about what we can expect from competition to Humira in 2023, how the first ophthalmology biosimilars are faring, and potential changes on the horizon at the FDA that could smooth the path to market for biosimilars sponsors.

Crucial Council Of EU Debate On Medical Device Regulation Crisis Countdown

The Council of EU’s agenda for the critical upcoming health council meeting confirms position of EU Medical Device Regulation in day’s running, along with other key health issues.

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts